DSIP dosage records
An amount in a paper comes attached to a subject, a route and an experimental question.
Intravenous human studies
The 1981 DSIP sleep study gave six middle-aged adults 25 nmol/kg intravenously. The unit expresses an amount relative to body weight. In that experiment, improved sleep appeared in the second hour, following slight arousal during the first.
The ACTH study in men used the same intravenous amount, but measured hormones rather than sleep. The withdrawal pilot also used 25 nmol/kg. Repetition of an amount across old experiments records a research choice; it has not established a safe or effective regimen for people.
I would file each of these numbers with its study, where the circumstances remain visible. There is no approved DSIP medicine and no validated human dosing standard.
Animal routes
The original rabbit experiment delivered DSIP into the brain. Other animal work used subcutaneous or intranasal administration, while some experiments exposed isolated tissue to the peptide. A result from one of those settings answers a different question from an intravenous human experiment.
The mouse ageing paper tested a DSIP-containing preparation. The 2024 insomnia experiment used an engineered fusion peptide in mice. Even before comparing amounts, the subject and the substance differ. Pooling these protocols under “DSIP peptide dosage” would conceal information essential to interpreting them.
Half-life and timing
Animal clearance work in dogs, monkeys and rats measured a plasma half-life of only a few minutes. Half-life is the time in which the circulating amount falls by half. Rapid degradation and binding to plasma proteins complicate the picture, and the review literature leaves human pharmacokinetics unvalidated.
The delayed sleep finding in the human paper and the rapid disappearance from animal blood are separate observations. I cannot join them into a timetable for human use. Blood clearance and the duration of an effect also ask different questions.
DSIP peptide nasal spray
Intranasal DSIP has been investigated in rats. The research record contains no human nasal-spray study and no approved spray. The original peptide's identity alone cannot settle what a different delivery route does.
DSIP also breaks down rapidly in plasma. No pharmaceutical product or validated stability standard has emerged from the work discussed here. The unresolved mechanism and uneven evidence leave ample reason for caution when a laboratory protocol is presented as practical guidance.